Inovio Pharmaceuticals, Inc. (INO)
Market Cap | 105.57M |
Revenue (ttm) | 9.62M |
Net Income (ttm) | -168.43M |
Shares Out | 268.08M |
EPS (ttm) | -0.65 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,743 |
Open | 0.394 |
Previous Close | 0.387 |
Day's Range | 0.375 - 0.394 |
52-Week Range | 0.375 - 2.610 |
Beta | 0.97 |
Analysts | Hold |
Price Target | 2.00 (+407.87%) |
Earnings Date | Nov 7, 2023 |
About INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medic... [Read more]
Financial Performance
In 2022, INO's revenue was $10.26 million, an increase of 478.23% compared to the previous year's $1.77 million. Losses were -$279.82 million, -7.85% less than in 2021.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for INO stock is "Hold." The 12-month stock price forecast is $2.0, which is an increase of 407.87% from the latest price.
News

INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
• Designation based on clinical evidence indicating INO-3107 may demonstrate substantial improvement over existing therapies • First Breakthrough Therapy designation for an INOVIO DNA medicine candida...

INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PLYMOUTH MEETING, Pa. , Aug. 29, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel...

INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update
Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter Scaling res...

INOVIO Reports Inducement Grants Under Inducement Plan
PLYMOUTH MEETING, Pa. , Aug. 4, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-asso...

INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023
PLYMOUTH MEETING, Pa. , July 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...

INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) -- INOVIO (NASDAQ:INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA:

INOVIO to Present at the 2023 Jefferies Healthcare Conference
PLYMOUTH MEETING, Pa. , May 25, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel...

INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
PLYMOUTH MEETING, Pa. , May 23, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...

INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the 11 (91%) patients saw a reduction in surgi...

New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles) Data indicates INO-3107 was well tolerated and has the potential to provide cl...

INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference
PLYMOUTH MEETING, Pa. , May 5, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...

INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023
PLYMOUTH MEETING, Pa. , April 28, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-a...

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023
Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5 th PLYMOUTH MEETING, Pa. , April 27, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a b...

European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107
European Commission to review and make a final decision, expected late May 2023 PLYMOUTH MEETING, Pa. , April 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developi...

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023
PLYMOUTH MEETING, Pa., April 12, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...

INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa. , April 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-as...

INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference
PLYMOUTH MEETING, Pa. , March 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel...

INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights
Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL) Trial results did not meet the prima...

INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
10 of 11 patients (91%) had a reduction in number of surgical interventions, measured from Day 0 to one year following initial treatment; 4 of the 10 patients did not need any surgery Treatment with I...

INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023
PLYMOUTH MEETING, Pa. , Feb. 15, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...

INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)
INO-4201 found to be well-tolerated in the trial Humoral responses were boosted in 100% (36 of 36) of treated participants PLYMOUTH MEETING, Pa. , Feb. 2, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a b...

INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates
Cost-saving measures include 11% headcount reduction Annual savings expected to be approximately $4.3 million Data readouts expected in first quarter of 2023 for key programs including INO-3107 for RR...

INOVIO Provides an Update on Lassa Fever and MERS Programs
PLYMOUTH MEETING, Pa. , Nov. 17, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious disease...

INOVIO Reports Financial Results and Highlights for the Third Quarter 2022
Announced positive interim data for INO-3107 as a potential first-in-class treatment for Recurrent Respiratory Papillomatosis Advanced strategy to focus on developing candidates that have the greatest...

INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800
PLYMOUTH MEETING, Pa. , Oct. 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases...